Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs — General
Establishes the minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements of the Act.
What this does not cover
stated in the document's own scope- Provides scope, status, and definitions only; the substantive manufacturing requirements for finished pharmaceuticals are in Part 211.
- Frames the drug cGMP regulations, not the medical-device Quality System Regulation (Part 820) or the food GMP rules (Part 117), which carry their own definitions.
- Applies to human and veterinary drugs; the medicated-feed and Type A article GMPs sit in Parts 225 and 226, which rely on Part 210’s definitions.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
21 CFR Part 210 is the short, general part that frames the finished-pharmaceutical GMP regulations that follow it in Part 211. It does three things: it states that the criteria in the cGMP regulations are the minimum current good manufacturing practice for methods, facilities, and controls used to manufacture, process, pack, or hold a drug; it sets out the applicability of those regulations, including that a failure to comply renders a drug adulterated; and it provides the definitions — terms such as batch, lot, component, drug product, and quality control unit — that Part 211 then uses throughout. It is the interpretive key to the substantive rules.
Scope & applicability
All drug manufacturers for human and veterinary use. Part 210 provides definitions and applicability scope; Part 211 provides the operational requirements.
Legal basis & how it acquires force
Like Part 211, Part 210 is a binding regulation in Title 21 CFR issued under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, resting on the same §501(a)(2)(B) adulteration standard. Part 210 does not add separate obligations so much as declare the legal status of the cGMP scheme — that the regulations state minimum practice and that non-conformance is an adulteration finding — and supply the vocabulary in which the enforceable requirements of Part 211 are written.
Document structure
| Part | Covers |
|---|---|
| §210.1 | Status of the current good manufacturing practice regulations — they are the minimum cGMP for the operations they cover |
| §210.2(a) | Applicability of the cGMP regulations across the drug parts, and how Parts 210 and 211 relate to the medicated-feed and Type A article GMPs (Parts 225 and 226) |
| §210.2(b) | The rule for conflicts between regulations, and the effect of non-conformance — a drug not made under cGMP is deemed adulterated |
| §210.3 | Definitions — the shared terms (batch, lot, component, drug product, quality control unit, and others) used across the cGMP parts |
Key requirements
- Defines the threshold for what constitutes GMP applicability
- Establishes that failure to comply constitutes adulteration under 21 U.S.C. 351(a)(2)(B)
- Provides definitions for all key terms used throughout Part 211
- Clarifies that the regulations in Part 211 are minimum standards
Implementation tips
- Use Part 210 definitions when scoping your quality system — "component" vs "drug product" distinctions matter for supplier qualification
- For combination products, FDA OCP guidance supplements Part 210 scope determinations
Revision notes
Part of the 2023 harmonisation update alongside Part 211. Definitions clarified.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Part 210 has no direct international counterpart because it is a framing and definitions part rather than a set of substantive requirements; its role is filled elsewhere by the scope and glossary sections of EU GMP and the PIC/S GMP Guide. Its significance is that it binds the definitions used across Parts 211, 225, and 226, so a term such as “batch” or “quality control unit” carries one consistent meaning throughout US drug GMP.
21 CFR Part 210: frequently asked questions
Quick answers to common questions about 21 CFR Part 210.
What is the purpose of 21 CFR Part 210?
It states the status of the cGMP regulations, their applicability, and the definitions used by the finished-pharmaceutical GMP requirements. It is the general framing part that Part 211 builds on.
Does Part 210 contain the actual GMP requirements?
No. The substantive requirements for finished pharmaceuticals are in Part 211. Part 210 supplies scope, status, and the shared definitions those requirements use.
Why are Parts 210 and 211 cited together?
Because they form one scheme: Part 210 declares that the regulations are the minimum cGMP and defines the terms, and Part 211 sets the enforceable practices. Neither is complete without the other.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.